Pharsight

Briviact generic

Briviact is an anticonvulsant drug owned by Ucb Inc. This medication, which contains the active ingredient brivaracetam, was first authorized for market use on May 12, 2016. The manufacturer has secured a total of 2 patents for Briviact, with none having expired as of now.

When will Briviact generic be available?

As for the availability of Briviact generic, it could hit the market after April 9, 2030. This date marks the expiry of the last patent (US10729653) titled 'Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives.'

Briviact uses

Briviact is used for the treatment of partial-onset seizures in patients aged 4 years and older. Its active ingredient, brivaracetam, effectively manages this condition, demonstrating the versatility of 2-oxo-1-pyrrolidine derivatives in medical practice.

Briviact patent expiration

Briviact currently holds 2 patents, with the last one set to expire on April 9, 2030. This effectively means that a Briviact generic could potentially be available after this date. Below are the details of the patent:

Litigations filed on Briviact

Briviact dosage

Want to ask something?